Recent Updates
Recently added Catalysts
REPL Negative Sentiment

REPLIMUNE FINAL DEADLINE ALERT: Bragar Eagel & Squire, P.C. Urges Replimune Group, Inc. Investors to Contact the Firm Regarding Class Action Lawsuit

Key Takeaway: Bragar Eagel & Squire, P.C. has announced a class action lawsuit against Replimune Group, Inc. for false and misleading statements made during the company's Class Period from November 22, 2024 to July 21, 2025. Allegations include the overstatement of the IGNYTE trial's prospects, which led the FDA to deem it inadequate. Investors who suffered losses must apply to the court by September 22, 2025, if they wish to be considered as lead plaintiffs.
Price reaction · baseline $3.225 (2025-09-19 close) · clean, no other REPL news in the window
day 0 close · peak
+1.4%

Market Sentiment Analysis

CONCERNS & RISKS

  • Class action lawsuit filed against Replimune due to alleged misleading statements.
  • Investors reported significant losses linked to overstatements regarding the IGNYTE trial's prospects.
  • Court application deadline for lead plaintiffs is approaching, creating urgency for affected investors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+816%
120-day peak, hindsight
Typical move
25.1%
average across 6 past catalysts
Cash runway
~8 mo
Medium dilution risk
Lead asset
RP1
Phase 2 · Non-Small Cell Lung Cancer (NSCLC)

Full Press Release Details

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Replimune (REPL) To Contact Him Directly To Discuss Their Options
If you purchased or acquired securities in Replimune between November 22, 2024 and July 21, 2025 and would like to discuss your legal rights, call Bragar Eagel & Squire partner Brandon Walker or Marion Passmore directly at (212) 355-4648.
Click here to participate in the action.
NEW YORK, Sept. 22, 2025 (GLOBE NEWSWIRE) --
Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, announces that a class action lawsuit has been filed against Replimune Group, Inc. (“Replimune” or the “Company”) (NASDAQ:REPL) in the United States District Court District Of Massachusetts on behalf of all persons and entities who purchased or otherwise acquired Replimune securities between November 22, 2024 and July 21, 2025, both dates inclusive (the “Class Period”).
Investors have until September 22, 2025 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
According to the lawsuit, defendants throughout the Class Period made false and/or misleading statements and/or failed to disclose that: (1) Defendants recklessly overstated the IGNYTE trial’s prospects, given material issues that defendants knew or should have known of, which resulted in the FDA deeming the IGNYTE trial inadequate and not well-controlled; and (2) as a result, defendants’ statements about Replimune’s business, operations, and prospects were materially false and misleading and/or lacked a reasonable basis at all times. When the true details entered the market, the lawsuit claims that investors suffered damages.
If you purchased or otherwise acquired Replimune shares and suffered a loss, are a long-term stockholder, have information, would like to learn more about these claims, or have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Brandon Walker or Marion Passmore by email at investigations@bespc.com, telephone at (212) 355-4648, or by filling out this contact form. There is no cost or obligation to you.
About Bragar Eagel & Squire, P.C.:
Bragar Eagel & Squire, P.C. is a nationally recognized law firm with offices in New York, California, and South Carolina. The firm represents individual and institutional investors in commercial, securities, derivative, and other complex litigation in state and federal courts across the country. For more information about the firm, please visit www.bespc.com. Attorney advertising. Prior results do not guarantee similar outcomes.
Follow us for updates on LinkedIn, X, and Facebook, and keep up with other news by following Brandon Walker, Esq. on LinkedIn and X.
Contact Information:
Bragar Eagel & Squire, P.C.
Brandon Walker, Esq.
Marion Passmore, Esq.

Frequently Asked Questions

Who can participate in the Replimune class action lawsuit?

Individuals or entities that acquired Replimune securities from November 22, 2024, to July 21, 2025, can participate.

What is the deadline to apply as lead plaintiff?

The deadline to apply for lead plaintiff status is September 22, 2025.

What did the lawsuit claim about Replimune's statements?

The lawsuit claims that Replimune made false statements about the IGNYTE trial's prospects.

How can investors contact Bragar Eagel & Squire?

Investors can contact Brandon Walker or Marion Passmore at (212) 355-4648.

Is there a cost to discuss legal options with the firm?

No, there is no cost or obligation to consult with the firm regarding claims.

Last updated: Sep 22, 2025